Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Molecular investigation for characteristic initiating mutations, in addition to clinical, haematological and histopathological evidence, has become an integral part of myeloproliferative neoplasm (MPN) diagnosis. Detection of the JAK2 V617F mutation and those within CALR exon 9, MPL exon 10 and JAK2 exon 12 can be performed by a variety of methodologies each possessing its own characteristics of sensitivity, specificity and clinical applicability.1 Mutation identification has been traditionally performed in a logical, stepwise fashion guided by other presenting features or increasingly in a simultaneous manner by next-generation sequencing (NGS). Up to 15% of patients with MPN of essential thrombocythaemia (ET) have no evidence of the canonical mutations (termed ‘triple-negative’) and are associated with a distinct clinical course particularly in regard to thrombotic risk therefore influencing treatment.2 Low JAK2 V617F allele burdens are by themselves insufficient to result in a diagnosis of an MPN in the absence …
Handling editor Mary Frances McMullin.
Contributors LK, LLT and SEL performed laboratory studies. CF, VM and KM provided patient care and clinical information. All authors contributed to manuscript preparation and approved the submitted version.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.